MBX Biosciences, Inc.
MBX$237M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCARMEL43 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
MBX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
MBX 2109
Hypoparathyroidism
400 µg of MBX 2109 once-weekly by subcutaneous injection
Hypoparathyroidism
MBX 1416 (INN imapextide)
Postbariatric Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MBX 2109 | Phase 2 | Hypoparathyroidism | - | - |
400 µg of MBX 2109 once-weekly by subcutaneous injection | Phase 2 | Hypoparathyroidism | - | - |
MBX 1416 (INN imapextide) | Phase 2 | Postbariatric Hypoglycemia | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply